Special Issue "Prevention of SARS-CoV-2 Infection and COVID-19: Safety, Immunogenicity and Effectiveness of Available Vaccines"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 23706
2. Occupational Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
Interests: occupational medicine; workplace safety and health; occupational epidemiology; biological risks; preventive medicine; healthcare settings and workers; digital health tools applied to occupational medicine
Special Issues, Collections and Topics in MDPI journals
The COVID-19 crisis is the greatest global challenge faced by the world in modern times. Since COVID-19 was declared a pandemic by the World Health Organization on 11 March 2020, approximately 270 million cases have been identified and there have been more than 5 million deaths worldwide. With this in mind, there has been unprecedented international effort, from both private and public institutions, to develop a vaccine against its causative agent, SARS-CoV-2. Vaccines represent a key preventive measure in the fight against infectious diseases, effectively reducing the morbidity and mortality caused by a specific pathogen among a susceptible population; however, unfortunately, the global burden of COVID-19 remains high, and evidence on the immunogenicity, safety and effectiveness of the current vaccines is still fundamental to guide further decisions on the ongoing immunization programmes. Clinical trial results can be influenced by various study biases; therefore, it is crucial to estimate these endpoints in real-world settings. In this Special Issue, we aim to gather high-quality evidence on the immunogenicity, safety and effectiveness of the currently available COVID-19 vaccines in different study populations. This will provide an evidence-based platform that will be extremely useful for the development of more accurate and effective public health strategies for COVID-19.
Prof. Paolo Durando
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- public health
- occupational medicine